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esponsibility of Xi’Abstract Polypill is a ﬁxed-dose combination that contains three or more active ingredients used as a
single daily pill to achieve a large effect in preventing cardiovascular disease with minimal adverse
effects. A novel and accurate liquid chromatography tandem mass spectrometry method using electrospray
ionization mode has been developed and validated for the simultaneous determination of amlodipine
(AMD), valsartan (VAL) using losartan (LOS) as an internal standard (IS), and hydrochlorothiazide
(HCT) using furosemide (FSD) as an IS. The separation was carried on Aquasil C18 (50 mm 2.1 mm,
5 mm) reversed phase column using acetonitrile and water containing 0.1% formic acid (50:50, v/v) as the
mobile phase. The method was validated in terms of linearity, accuracy and precision over the
concentration range of 1–1000 ng/mL. The intra and inter-day precision and accuracy, stability and
extraction recoveries of all the analytes were in the acceptable range. This method can be successfully
applied to the pharmacokinetic study of AMD, VAL and HCT when given as a polypill.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.sity. Production and hosting by Elsev
3
93004; fax: þ914027193753.
co.in (S.G. Gadepalli).
an Jiaotong University.1. Introduction
Control of hypertension is important for the prevention of cardio-
vascular risk factors. Calcium channel blockers have been widely
used in the treatment of hypertension and are often prescibed in the
treatment of hypertension and/or angina pectoris [1]. Combination
therapy of calcium channel blockers with an angiotensin II receptor
blocker and a diuretic would be expected to provide enhancedier B.V. All rights reserved.
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is a triple drug polypill approved by US-FDA [3] available in market
that contains amlodipine (AMD), valsartan (VAL) and hydrochlor-
othiazide (HCT) in a single pill [4,5]. Polypills are the ﬁxed-dose
combinations (FDC) of three or more active ingredients in a single
pill with the intention of reducing the number of tablets or capsules
that need to be taken to achieve a large effect in preventing
cardiovascular disease with minimal adverse effects [6,7].
AMD, chemically known as 2-[(2-amino ethoxy)-methyl]-4-
(2-cholophenyl)-1,4-dihydro-6-methyl-3,5-pyridine dicarboxylic
acid 3-ethyl-5-methyl ester, benzosulfonate, is a dihydropyridine
derivative [8–10] with calcium antagonist activity used in the
management of hypertension, chronic stable angina pectoris and
prinzmetal variant angina [11]. After oral administration AMD is
slowly and almost completely absorbed and peak plasma concentra-
tions are attained within 6–12 h. AMD has a relatively high oral
bioavailability of 60–65%, which is not inﬂuenced by food. More-
over, AMD appears to have a linear pharmacokinetic proﬁle, with
strong positive correlations between oral dosage, Cmax and AUC0–72.
In healthy volunteers, steady-state plasma concentrations are achieved
after 7 once daily oral doses, without evidence of accumulation.
AMD has a large volume of distribution of 21 L/kg, and is more than
95% bound to plasma proteins [12]. VAL is an effective nonpeptide
angiotensin II receptor antagonist, chemically N-(1-oxopentyl)–N-
[[20-(1H-tetrazol-5-yl) [1,10-biphenyl]-4-yl] methyl]-L-valine [13,14].
VAL displaces angiotensin II from the AT1 receptor and produces its
blood pressure lowering effects by antagonizing AT1-induced
vasoconstriction, aldosterone release, catecholamine release, arginine
vasopressin release, water intake and hyper tropic responses, which
results in blocking of the cardiovascular effects of Angiotensin II
[15,16]. Peak plasma concentration was reached 2 h after oral
administration and then declined with a terminal half-life of 3–7 h
[17–19]. The maximum plasma concentrations after single oral dose
of VAL (160 mg) reach 2–4 mg/mL. The drug is only minimally
metabolized and excreted largely (about 80%) as unchanged com-
pound [20,21]. HCT is a benzathiadiazine diuretic, chemically known
as 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-
1,1-dioxide, used in hypertension often prescribed in combination
with other antihypertensive drugs such as beta blockers, angiotensin-
converting enzyme inhibitors, or angiotensin II receptor blockersFig. 1 Chemical stru[22,23]. The bioavailability of HCT in human is 60–80%, and is
independent of the dose over the range of 25–200 mg. After oral
administration, peak plasma concentration is achieved at 2 h and the
half-life of elimination averages 10 h [24,25].
Several chromatographic techniques have been reported for AMD
[1,9,26–28], VAL [15,21,22,29,30] and HCT [22,31–33] individually
and in combination with other drugs. However, so far, no single
method has been reported for the simultaneous estimation of AMD,
VAL and HCT in rat plasma by LC–MS/MS. Therefore, the aim of
this study was to evaluate the pharmacokinetic parameters of these
three drugs when used as a polypill. The developed bioanalytical
method has been validated according to ICH guidelines [34] and
successfully applied to pharmacokinetic study in rats. This method can
also be useful in estimating the plasma samples of patients receiving
Exforge HCT. The structures of analytes are presented in Fig. 1.2. Experimental
2.1. Chemicals and apparatus
The reference standards of AMD, VAL, HCT, losartan (LOS), and
furosemide (FSD) were obtained from Aurobindo Pharma Ltd.
(Hyderabad, India). Their structures and purities were conﬁrmed by
HPLC, nuclear magnetic resonance and high resolution mass spectro-
metric methods. All the chemicals were more than 95% pure. High
purity deionized water was obtained using a Direct Q ultra-pure water
system from Millipore (Milford, MA, USA). HPLC grade acetonitrile
and methanol were purchased from E-Merck (Mumbai, India).
Analytical grade formic acid and glacial acetic acid were purchased
from SD-Fine Chemicals Ltd. (Mumbai, India). 0.45 Syringe ﬁlters
with nylon membrane was obtained from Pall scientiﬁc, Bangloor
(KA, USA). Spinix Vortex shaker was obtained from Jaibro Scientiﬁc
Works (New Delhi, India). Biofuge refrigerated centrifuge was
purchased from Heraeus (Germany).
2.2. Standard solutions and fortiﬁcation
Standard stock solutions of AMD, VAL, HCT were prepared by
accurately weighing 10 mg of each standard on a closed electronicctures of analytes.
Amlodipine, valsartan and hydrochlorothiazide in rat plasma 401microbalance (Sartorius, Berlin, Germany) and dissolving them
separately in 10 mL of acetonitrile. Calibration standard and quality
control (QC) samples in plasma were prepared by adding correspond-
ing working solutions with drug-free rat plasma.
A volume of 10 mL of appropriate diluted stock solutions of
mixture of drugs (AMD, VAL and HCT) at different concentra-
tions and 10 mL of ISs (LOS and FSD) at a ﬁxed concentration
were spiked into 100 mL of drug-free rat plasma to yield ﬁnal
concentrations of calibration samples 1, 2, 5, 10, 20, 50, 100, 200,
500 and 1000 ng/mL for AMD, VAL and HCT, respectively. The
ﬁnal concentration of ISs (LOS and FSD) was 20 ng/mL. Similarly,
QC samples were prepared at four concentration levels LLOQ (1 ng/
mL), two MLOQs (5 and 50 ng/mL) and HLOQ (500 ng/mL) for
AMD, VAL and HCT.2.3. Sample preparation
Analytes were extracted from plasma by employing the protein
precipitation method. 200 mL of acetonitrile was added as a protein
precipitating agent, vortexed for 1 min and then centrifuged at
10,000 rpm for 10 min on Biofuge refrigerated centrifuge at 4 1C.
The supernatant layer was separated and ﬁltered through 0.45 mm
syringe ﬁlters and 20 mL of the solution was injected for LC–MS/
MS analysis.2.4. Instrumentation
The LC–MS/MS analysis was carried out in electrospray ionization
(ESI) positive mode for AMD and VAL using LOS as IS and in
negative ion ESI mode for HCT using FSD as IS on a Thermo
Finnigan LCQ Advantage Max ion trap mass spectrometer coupled to
a Thermo Finnigan HPLC system containing surveyor LC quaternary
pump plus, surveyor auto-sampler plus (Thermo Scientiﬁc, USA). The
Xcalibur software (version 2.1) was used for data acquisition and
analysis. The separation of all the analytes was carried out on an
Aquasil-C18 (50 mm length 2.1 mm internal diameter and 5 mm
particle size) column. Temperature was set to 20 1C. The mobile phase
composed acetonitrile and water (50:50, v/v) containing 0.1% formic
acid for separation of AMD and VAL (LOS as IS) at a ﬂow rate of
0.2 mL/min for 3 min and the isocratic mobile phase comprised
acetonitrile and water (60:40, v/v) containing 0.1% glacial acetic acid
used for HCT (FSD as IS) at a ﬂow rate of 0.2 mL/min for 5 min. The
full scan MS and MS/MS spectra of each analyte were obtained by
direct infusion of the respective sample solution at a concentration of
10 mg/mL solution prepared in the mobile phase. The ﬂow rates of
sheath gas and auxiliary gas were optimized and set to 30 psi and 5 psi,
respectively. The needle spray voltage was set to 4.5 kV. Helium was
used as collision gas tuned for each analyte to obtain good signal
intensity in MS2 experiment. The drugs were analyzed using multipleTable 1 Optimized LC–MS/MS conditions for AMD, VAL, LOS, H
Analyte RT (min) ESI mode
AMD 0.79 Positive
VAL 2.19 Positive
LOS 1.11 Positive
HCT 1.34 Negative
FSD 3.60 Negativereactions monitoring (MRM) mode. The precursor ions, product ions,
and LC–MS/MS parameters are depicted in Table 1.
2.5. Method validation
The bioanalytical method was validated according to the FDA
guidelines (US Food and Drug Administration, May 2001). The
method was validated in terms of selectivity, speciﬁcity, linearity,
limit of detection (LOD), limit of quantiﬁcation (LOQ), accuracy,
precision, recovery, matrix effect and stability.
The selectivity and speciﬁcity were assessed by comparing the
chromatograms of six different sources of blank rat plasma with
those of the corresponding spiked plasma. Each blank plasma
sample was tested using the proposed extraction procedure and
LC–MS/MS conditions to ensure no interference of AMD, VAL,
HCT, and the ISs from blank plasma. The linearity of the assay
was evaluated by constructing calibration curves with different
concentrations ranging from 1 to 1000 ng/mL for AMD, VAL and
HCT. The calibration curves were constructed by plotting each
respective peak area ratios of AMD and VAL to LOS (IS) and
HCT to FSD (IS) against the concentrations of AMD, AVL and
HCT, respectively, using the weighting factor of 1/x2.
LODs of the drugs were determined based on signal intensity
three times more than baseline noise (S/N¼3) and LOQs of the
drugs were determined based on intensity of signal which was ten
times more than the noise (S/N¼10).
QC samples were prepared in blank plasma at the concentra-
tions of 1 (LLOQ), 5, 50 (MLOQs) and 500 (HLOQ) ng/mL for
AMD, VAL and HCT in six replicates (n¼6) for assessing the
accuracy, intra- and inter-day precisions (reproducibility) of the
method. All QC samples were prepared freshly on three con-
secutive days and analyzed in each analytical batch along with the
unknown samples.
The matrix effect and recoveries of analytes were quantitatively
measured by comparing the signal intensities and the peak area
ratios (analyte/IS) obtained from postextraction spiking (A)
(extracting 100 mL of rat plasma with 1 mL of acetonitrile. The
residues, after evaporation of solvent by nitrogen purging, were
reconstituted with 10 mL of standard solution containing AMD,
VAL and HCT at concentrations of 5, 50 and 500 ng/mL and
internal standards LOS and FSD at 20 ng/mL) and standard
solutions (B) (samples prepared in mobile phase) at the same
concentrations in six replicates (n¼6). The ratio (A/B 100%)
was used to evaluate the matrix effect.
The stabilities of AMD, VAL and HCT in plasma at different
storage conditions were evaluated and the results were expressed as
mean percentage accuracies. The short-term stability was deter-
mined by keeping QC samples in six replicates (n¼6) at room
temperature for 24 h. The autosampler stability was evaluated by
keeping the QC samples at 4 1C for 24 h in autosampler before
analysis. Freeze–thaw stability of QC samples was analyzed afterCT and FSD.
MRM transitions CE (eV)
409-238 25
436-418 30
423-405 40
296-268 30
328-285 35
S.G. Gadepalli et al.402three freeze–thaw cycles by freezing at 80 1C for 24 h and
thawing at room temperature for 24 h.
2.6. Animal study
Six healthy female Sprague-Dawley rats with an average weight of
200710 g were procured from National Institute of Nutrition, Tarnaka,
Hyderabad (India). The animals were housed in BIOSAFE, under
standard (2272 1C, 60–70% humidity) laboratory conditions, main-
tained on a 12-h natural day–night cycle, with free access to standard
food and water. Animals were acclimatized to laboratory conditions
before the study. The experimental protocol was approved by the
Institutional Animal Ethical Committee (IAEC) of IICT, Hyderabad
(India) and was conducted according to the CPCSEA guidelines on the
use and care of experimental animals. After overnight fasting of
animals, the mixture of AMD, VAL and HCT was prepared and
administered orally to the rats as gum acacia suspension at a dosage of
1, 15 and 2.5 mg/kg, respectively. A volume of 0.25 mL of blood was
collected by retro-orbital puncture into EDTA coated glass tubes at
time intervals of 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 h
after drug administration. Blood was centrifuged at 5000 rpm for
10 min and the plasma was separated and stored at 80 1C until
analysis. Pharmacokinetic parameters were estimated using non-com-
partmental analysis with RAMKIN GW-BASIC (Ver. 3.22) software.3. Results and discussion
3.1. Mass spectrometric and chromatographic conditions
To optimize peak shape with appropriate retention time
various combinations of mobile phases were investigated.Fig. 2 LC–ESI-MS/MS spectra of (A) amlodipine, (B) valsartaSeparation of these drugs was attempted using various combi-
nations of acetonitrile and water with different percentage of
modiﬁers. The best separation was achieved with acetonitrile
and water in the ratio of 50:50 (v/v) containing 0.1% formic
acid for estimating AMD, VAL and LOS. The optimized
mobile phase for HCT and FSD was acetonitrile and water
in the ratio of 60:40 (v/v) containing 0.1% glacial acetic acid.
The reversed-phase Thermo Aquasil C18 column (50 mm 2.1
mm, 5 mm) protected by Phenomenex security guard column
C18 (4 mm 2 mm i.d.) (Phenomenex, India) was used with a
ﬂow rate of 0.2 mL/min in both the methods. The retention
times of AMD, VAL and LOS were found to be 0.79, 2.19 and
1.34 min, respectively. The retention times of HCT and FSD
were 1.11 and 3.60 min, respectively. The total chromato-
graphic run time was 3.0 min in estimating AMD, VAL and
LOS whereas 5.0 min for HCT and FSD.
The standard solutions of 10 mg/mL with respect to AMD,
VAL and LOS in 50% acetonitrile containing 0.1% formic acid
were infused directly into the mass spectrometer ESI source in
positive ion mode and HCT and FSD in negative ion mode. The
observed full scan mass spectra in positive mode showed
prominent protonated molecular ions [MþH]þ of m/z 408,
435, and 422 for AMD, VAL and LOS, respectively, and
prominent deprotonated molecular ions [MH] of m/z 297
and 330 for HCT and FSD, respectively, in negative ion mode.
The [MþH]þ ions and [MH] ions of respective analytes
were subjected to collision- induced dissociation (CID) at
average collision energy of 30%. The collision energies
were optimized for each analyte to obtain the most intense
fragment ions. The molecules underwent fragmentation to yield
the following fragment ions of m/z 238, 418, 405, 268, and 285.
The MS/MS spectra of analytes are presented in Fig. 2. Basedn, (C) losartan, (D) hydrochlorothiazide and (E) furosemide.
Fig. 3 LC–ESI-MRM chromatograms of (A) blank plasma, (B) spiked plasma at 1 ng/mL, and (C) plasma extracted from rats after 1 h of oral
administration.
Table 2 Intra-day and inter-day variation for AMD, VAL and HCT in six replicates (n¼6) at each concentration.
Analyte Concentration (ng/mL) Intra-day Inter-day
Accuracy (%) RSD (%) Accuracy (%) RSD (%)
AMD 1 93.4 8.3 86.2 11.4
5 87.9 5.8 92.4 7.2
50 98.2 9.3 105.7 9.3
500 106.3 5.8 110.0 8.3
VAL 1 89.3 12.4 85.7 13.5
5 91.8 6.2 93.6 11.4
50 103.4 9.4 107.0 9.2
500 95.3 6.7 89.3 6.2
HCT 1 88.7 12.2 86.4 14.3
5 89.9 9.4 88.2 9.1
50 92.9 8.3 90.2 3.9
500 95.3 8.4 96.8 5.3
Amlodipine, valsartan and hydrochlorothiazide in rat plasma 403on their mass spectra and tandem mass spectra, the following
MRM transitions: m/z 409-238, m/z 436-418, m/z 296-
268, m/z 423-405, m/z 329-285, were selected for analysisof AMD, VAL, LOS, HCT and FSD, respectively. The
structures of these drugs and their putative fragments were also
conﬁrmed through high resolution mass spectrometry (HRMS)
S.G. Gadepalli et al.404by measuring their accurate masses. The HRMS analysis was
carried out on an Exactive bench top Orbitrap mass spectro-
meter (Thermo Scientiﬁc, USA).Table 3 Recovery values of AMD, VAL and HCT (n¼6).
Analyte Concentration
(ng/mL)
Mean
recovery7SD
(%)
RSD
(%)
AMD 5 86.377.5 6.1
50 89.275.7 9.5
500 92.576.2 4.7
VAL 5 86.478.2 5.2
50 88.774.2 8.4
500 90.179.1 5.2
HCT 5 89.3710.5 9.2
50 90.276.4 8.4
500 86.775.2 8.4
Table 4 Stability studies of AMD, VAL and HCT in rat plasma at
Storage conditions AMD
Mean
accuracy
(%)
Short term stability (24 h, room temperature) 92.5
Freeze/thaw stability (3 cycles) 95.4
Pre-preparative stability at 4 1C for 12 h (autosampler) 94.3
Fig. 4 Mean plasma concentration–time proﬁle of (A) amlodipine, (B) v
mean7SD (n¼6).3.2. Method validation
The speciﬁcity of this method was conﬁrmed by comparing
chromatograms of blank plasma, spiked plasma with analytes at
a concentration of 1 ng/mL and plasma sample obtained after 1 h
of oral administration shown in Fig. 3. AMD, VAL and LOS (IS)
in positive ESI experiment and HCT and FSD (IS) in negative ESI
experiment were well separated under the described chromato-
graphic conditions. No interfering endogenous peaks were
observed around their retention times.
The calibration curves of the analytes showed a good linearity
over the studied concentration range of 1–1000 ng/mL for AMD,
VAL and HCT with correlation coefﬁcients (r2) 0.9993, 0.9997
and 0.9997, respectively. The LODs for all studied analytes were
found to be 0.5 ng/mL. The LLOQs for all analytes were 1 ng/mL
with acceptable precision and accuracy, which was sufﬁcient
to perform pharmacokinetic studies of AMD, VAL and HCT
in rats.
The intra- and inter-day precisions for AMD, VAL and HCT were
less than 14.3%. The obtained intra-day accuracies were in the
range of 87.9–106.3% and inter-day accuracies were in the range of
85.7–110%. The validation parameters are depicted in Table 2.three QC levels (n¼6).
VAL HCT
RSD
(%)
Mean
accuracy
(%)
RSD
(%)
Mean
accuracy
(%)
RSD
(%)
9.7 104.6 6.1 89.4 11.5
7.4 91.5 9.8 87.3 7.3
8.6 106.2 4.7 91.6 8.4
alsartan and (C) hydrochlorothiazide in rats. Each point represents the
Table 5 Pharmacokinetic parameters of AMD, VAL, and HCT in rats (n¼6).
Parameter AMD VAL HCT
Cmax (ng/mL) 24.7673.85 4390.917678.54 516.13774.18
Tmax (h) 3.2070.45 1.6070.22 1.1070.22
AUC0 t (ng mL/h) 181.51744.60 7517.637847.70 1037.617175.24
AUC01(ng mL/h) 200.31756.47 7633.507824.10 1053.147182.42
t1/2 (h) 13.0373.20 4.1170.28 3.9070.47
Cmax, the maximum plasma concentration; Tmax, the time to reach Cmax; t1/2, elimination half-life; AUC0-t, the area under the plasma concentration–
time curve from time zero to the last sampling time; AUC0-1, the area under the plasma concentration–time curve from time zero to inﬁnity.
Amlodipine, valsartan and hydrochlorothiazide in rat plasma 405The extraction recoveries of all drugs from rat plasma were in
the range of 86.3–92.5% with relative standard deviations less than
10%, which indicates the sample preparation technique is suitable
for extracting the studied drugs from rat plasma. The recovery
results are displayed in Table 3.
The stability studies of these drugs were performed at three QC
concentration (low, medium and high) levels in six replicates
(n¼6). The predicted concentrations for each analyte deviated
within 713% of nominal concentrations after storage of plasma
samples at room temperature for 24 h, three freeze–thaw cycles
and in autosampler for 12 h at 4 1C. The mean accuracies were
found to be more than 87% with relative standard deviations less
than 12%, which are summarized in Table 4.3.3. Application to pharmacokinetic study
The established method was successfully applied to analysis of
plasma samples after an oral administration of 1, 15 and 2.5 mg/kg
of AMD, VAL and HCT simultaneously. The mean plasma
concentration–time proﬁle of AMD, VAL and HCT is shown in
Fig. 4. A non-compartmental model was used to estimate the
pharmacokinetic parameters of AMD, VAL and HCT in rat
plasma, the results are shown in Table 5. After oral administration
of the three drugs, peak plasma concentrations (Cmax) were
reached at the time to reach maximum concentration (Tmax) of
3.2070.45 h, 1.6070.22 h and 1.1070.22 h with an elimination
half-life (t1/2) of 13.0373.20 h, 4.1170.28 h and 3.9070.47 h for
AMD, VAL and HCT, respectively. Thus the developed method
was successfully applied for pharmacokinetic study in rats after
oral administration of AMD, VAL and HCT in combination.4. Conclusion
We have developed and validated a highly sensitive, speciﬁc,
reproducible and high throughput LC–MS/MS assay to quantify
AMD, VAL and HCT simultaneously in rat plasma. Simple and
single step protein precipitation was used to extract analytes from
rat plasma. The major advantages of the assay are simple sample
preparation and short run time. The obtained LODs and LOQs of
all the drugs were adequate to perform the pharmacokinetic study
in rat plasma. Based on the results, we can conclude that the
present method is not only suitable for assessing the pharmaco-
kinetics of Exforge HCT™ polypill in preclinical but also
applicable for clinical pharmacokinetics.Acknowledgements
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